WO2000027883A3 - A method of treating tumors using fas-induced apoptosis - Google Patents

A method of treating tumors using fas-induced apoptosis Download PDF

Info

Publication number
WO2000027883A3
WO2000027883A3 PCT/US1999/026221 US9926221W WO0027883A3 WO 2000027883 A3 WO2000027883 A3 WO 2000027883A3 US 9926221 W US9926221 W US 9926221W WO 0027883 A3 WO0027883 A3 WO 0027883A3
Authority
WO
WIPO (PCT)
Prior art keywords
fas
tumor cell
induced apoptosis
treating tumors
fasl
Prior art date
Application number
PCT/US1999/026221
Other languages
French (fr)
Other versions
WO2000027883A2 (en
WO2000027883B1 (en
Inventor
Jian-Yun Dong
James S Norris
Original Assignee
Musc Found For Res Dev
Dong Jian Yun
James S Norris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Musc Found For Res Dev, Dong Jian Yun, James S Norris filed Critical Musc Found For Res Dev
Priority to AU13442/00A priority Critical patent/AU1344200A/en
Priority to EP99956943A priority patent/EP1127075A2/en
Priority to JP2000581060A priority patent/JP2002529068A/en
Priority to CA002347847A priority patent/CA2347847A1/en
Publication of WO2000027883A2 publication Critical patent/WO2000027883A2/en
Publication of WO2000027883A3 publication Critical patent/WO2000027883A3/en
Publication of WO2000027883B1 publication Critical patent/WO2000027883B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C12N2830/006—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB tet repressible

Abstract

The present invention provides a method of killing a Fas+ tumor cell comprising introducing into a second tumor cell a nucleic acid encoding a Fas ligand (FasL), whereby the second tumor cell expresses the nucleic acid thereby producing FasL, and whereby interaction of the Fas+ tumor cell with the second tumor cell expressing FasL causes the Fas+ tumor cell to undergo apoptosis, thereby killing the Fas+ tumor cell.
PCT/US1999/026221 1998-11-06 1999-11-05 A method of treating tumors using fas-induced apoptosis WO2000027883A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU13442/00A AU1344200A (en) 1998-11-06 1999-11-05 A method of treating tumors using fas-induced apoptosis
EP99956943A EP1127075A2 (en) 1998-11-06 1999-11-05 A method of treating tumors using fas-induced apoptosis
JP2000581060A JP2002529068A (en) 1998-11-06 1999-11-05 Methods of treating tumors using FAS-induced apoptosis
CA002347847A CA2347847A1 (en) 1998-11-06 1999-11-05 A method of treating tumors using fas-induced apoptosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10736398P 1998-11-06 1998-11-06
US60/107,363 1998-11-06

Publications (3)

Publication Number Publication Date
WO2000027883A2 WO2000027883A2 (en) 2000-05-18
WO2000027883A3 true WO2000027883A3 (en) 2000-07-27
WO2000027883B1 WO2000027883B1 (en) 2000-09-14

Family

ID=22316259

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/026221 WO2000027883A2 (en) 1998-11-06 1999-11-05 A method of treating tumors using fas-induced apoptosis

Country Status (5)

Country Link
EP (1) EP1127075A2 (en)
JP (1) JP2002529068A (en)
AU (1) AU1344200A (en)
CA (1) CA2347847A1 (en)
WO (1) WO2000027883A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2585775C (en) 2004-10-29 2013-10-01 Musc Foundation For Research Development Cationic ceramides, and analogs thereof, and their use for preventing or treating cancer
EP1814841A4 (en) * 2004-10-29 2011-03-16 Musc Found For Res Dev Ceramides and apoptosis-signaling ligand
CN102368905B (en) 2008-11-06 2015-04-01 南卡罗来纳医科大学研究发展基金会 Lysosomotropic inhibitors of acid ceramidase

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033617A1 (en) * 1996-03-13 1997-09-18 Protein Design Labs, Inc. Fas ligand fusion proteins and their uses
WO1998037185A2 (en) * 1997-02-20 1998-08-27 The Board Of Regents Of The University Of Texas System Vectors for controlled gene expression

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033617A1 (en) * 1996-03-13 1997-09-18 Protein Design Labs, Inc. Fas ligand fusion proteins and their uses
WO1998037185A2 (en) * 1997-02-20 1998-08-27 The Board Of Regents Of The University Of Texas System Vectors for controlled gene expression

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ARAI H. ET AL.: "Gene transfer of Fas ligand induces tumor regression on vivo", PROC. NATL. ACAD. SCI. USA, vol. 94, December 1997 (1997-12-01), pages 13862 - 13867, XP002128638 *
DROZDZIK M., ET AL.: "Antitumor effect of fibroblast engineered to express fas ligand, (FASL) on hepatocellular carcinoma (HCC).", XP002128641, Retrieved from the Internet <URL:http://www.easl.mailcom.pt/GS4_21.html> [retrieved on 20000125] *
LEON R.P. ET AL.: "Adenoviral-mediated gene transfer in lymphocytes.", PROC. NATL. ACAD. SCI. USA, vol. 95, October 1998 (1998-10-01), pages 13159 - 13164, XP002128639 *
ZHANG H.-G. ET AL.: "Application of a Fas ligand encoding recombinant adenovirus vector for prolongation of transgene expression", J. VIROLOGY, vol. 72, no. 3, March 1998 (1998-03-01), pages 2483 - 2490, XP002128640 *

Also Published As

Publication number Publication date
WO2000027883A2 (en) 2000-05-18
EP1127075A2 (en) 2001-08-29
WO2000027883B1 (en) 2000-09-14
JP2002529068A (en) 2002-09-10
CA2347847A1 (en) 2000-05-18
AU1344200A (en) 2000-05-29

Similar Documents

Publication Publication Date Title
WO2001051633A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2001092581A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2002089747A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2001072295A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO1998037093A3 (en) Compounds for immunotherapy of prostate cancer and methods for their use
WO2002074156A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
NO991691D0 (en) Cancer immunotherapy using tumor cells combined with mixed lymphocytes
EP1734122A3 (en) APO-2 ligand
AU584608B2 (en) DNA encoding human tumor necrosis factor and human tumor necrosis factor polypeptide
WO2002004514A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
IL134537A0 (en) Nucleic acid encoding an april ligand or a fragment thereof, vectors and host cells containing the same and methods for the production thereof
WO2002074237A3 (en) Compositions and methods for the therapy and diagnosis of kidney cancer
WO2002092001A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002012328A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2003039458A3 (en) TREATMENT OF HUMAN CANCER WITH ADENOVIRAL VECTOR EXPRESSING TNF-α
HUP0103961A2 (en) Carbon black, method for producing carbon black and use of the same
AU2759199A (en) Human platelet heparanase polypeptides, polynucleotide molecules that encode them, and methods for the identification of compounds that alter heparanase activity
WO2002066044A3 (en) Method for dendritic cells based immunotherapy of tumors using combination therapy
AU4224599A (en) Anti-prostate cancer vaccines, and methods of making, using and evaluating the same
IL135911A0 (en) Dna 19355 polypeptide, a tumor necrosis factor homolog
WO2002058534A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2003037267A8 (en) Compositions and methods for the therapy and diagnosis of lung cancer
EP1131107A4 (en) Antisense modulation of inhibitor-kappa b kinase-alpha expression
EP1131332A4 (en) Antisense modulation of inhibitor-kappa b kinase-beta expression
WO2000027883A3 (en) A method of treating tumors using fas-induced apoptosis

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 13442

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: B1

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

B Later publication of amended claims
ENP Entry into the national phase

Ref document number: 2347847

Country of ref document: CA

Ref country code: CA

Ref document number: 2347847

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 581060

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 13442/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999956943

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09600521

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999956943

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999956943

Country of ref document: EP